This presentation will provide an overview of two new Invitrogen data analysis software apps available on the Thermo Fisher™ Connect Platform to analyze data acquired on Luminex® xMAP instruments. The Invitrogen™ QuantiGene Plex Data Analysis software is used to analyze differential gene expression data generated using the Invitrogen QuantiGene Plex Assays, while the Invitrogen™ ProcartaPlex™ Analysis App, enables data analysis of Invitrogen™ ProcartaPlex™ or other xMAP based multiplex immunoassays. We will demonstrate importing of assay data, selection of analysis template, sample information annotation, assigning lot specific information, the use of various data quality control features, curve fit options, calculating fold changes and configurable custom report generation. In addition, we will discuss the use of Transcriptome Analysis Console (TAC) Software for advance data analysis and visualization for gene expression data.

Glioblastoma (GBM) and brain metastases are lethal neoplastic disorders with limited treatment options and where pathogenesis is modulated by multiple cytokines. It is possible that cytokines released from glioblastoma or brain metastatic tissues, as well as from immune cells in the tumor microenvironment, can be non-invasively identified in the circulation. Identifying these biomarkers and developing unique molecular profiles of multiple interacting biomarkers in human plasma may have important utility in differentially diagnosing and staging both primary and secondary intracranial tumors, tracking disease progression, estimating prognoses, selecting optimal management strategies, and following treatment responses. Investigators today are challenged with choosing an assay that offers the highest sensitivity for cytokine detection and results in meaningful data. In this presentation, Dr. Diane Bender will describe a study which compared the performance of the MILLIPLEX® MAP Human High Sensitivity T Cell Magnetic Bead Panel with MSD V-Plex cytokine assay kits to quantify circulating cytokines in human plasma from brain cancer patients and healthy controls. The evaluation parameters included quantification limits, dynamic range, detection rate, and labor time to determine real-life performance for rapidly quantifying multiple cytokines in small-volume human plasma samples.

The use of biological molecules as drugs are becoming increasingly common and an essential part of the pharmacological repertoire. However, exposure to these biological molecules carries a risk of eliciting an anti-drug immune response producing anti-drug antibodies (ADAs). These ADAs may impact the function of the drug or contribute to unwanted immune responses.  Currently, characterization of anti-drug immune responses requires multiple tiered screening and confirmation steps to: a) detect and confirm the presence of anti-drug-specific antibodies, b) determine the titer of ADAs and c) evaluate ADA isotypes and drug-neutralization capacity. In this presentation, Dr. Paul Rhyne will describe how he combined all of the above mentioned ADA screening requirements into a single multiplex immunoassay for Humira® (adalimumab), a human monoclonal IgG1 antibody that binds TNFα. This immunoassay can comprehensively characterize anti-drug antibody responses in a simple overnight procedure. The multiplex immunoassay was developed on the Luminex® FLEXMAP® 3D platform to rapidly and effectively screen patient serum samples for anti-Humira® antibody activity while simultaneously characterizing and isotyping the ADAs including IgG1, IgG2, IgG3, IgG4, IgM, IgE, and IgA.

Meet xMAP Technology all over again. Over the past 25 years, Luminex’s xMAP Technology has emerged as the worldwide leader in bead-based multiplexing. With the new xMAP INTELLIFLEX, we have revitalized the xMAP platform with a modernized instrument that can deliver double the results in a single well as compared to the FLEXMAP 3D.

Join us to learn about exciting applications of xMAP Technology and the notable research that is being achieved on this trusted, robust platform. We’ll discuss the potential impact of the INTELLIFLEX in this field, highlighting the dual reporter feature of this fast, flexible, and intuitive newest member of the xMAP family.